University of Florida
Gainesville, Florida, 32610, United States
NCT Number: NCT06203392
Preclinical data indicate that very low carbohydrate ketogenic diets (KD) may prevent progression of age-related sarcopenia (skeletal muscle decline) but also may disturb bone metabolism. The investigators will pilot test a randomized trial comparing the effects of short-term adaptation to a well-formulated ketogenic diet and Mediterranean diet on markers of bone metabolism and muscle function in older adults. The expected results will help inform the benefit-risk assessment for older patients considering longer term use of KD therapy.
Looking for future studies?
Notify Me55 year–80 year
All sexes
Interventional
Not applicable
Gainesville, Florida, 32610, United States
Eucaloric very low carbohydrate ketogenic diets (KD) are therapeutic diets that mimic fasting by generating ketones for metabolic fuel while meeting nutritional requirements (nutritional ketosis). Nutritional ketosis may broadly benefit healthspan through mechanisms such as suppression of inflammation or induction of autophagy, and preclinical and emerging clinical data indicate that KD therapy may help slow progression of age-related conditions including sarcopenia. However, questions remain about the benefits and risks of KD, especially relative to recommended therapeutic diets such as the Mediterranean Diet (MD) for which there is evidence of benefit for age-related conditions. For example, KD has shown efficacy for weight loss, which could reduce ectopic lipid accumulation that weakens muscle and bone. KD has been shown to increase skeletal muscle mitochondrial mass, mitochondrial activity, and strength in aged mice, possibly by increasing peroxisome proliferator-activated receptor activity and preserving fast-oxidative fibers that typically decline with age. However, long term use of KD may adversely impact bone. KD can cause deterioration of bone in juvenile mice without evidence of undernutrition and is associated with skeletal demineralization in children being treated for drug-resistant epilepsy.
Given the burden of musculoskeletal disease in older Americans, it is vital to understand the effects of KD on the musculoskeletal system of older adults to inform the benefit-risk assessment for an older patient and to optimize the effectiveness of KD for age-related conditions. The investigators are conducting a pilot test of a randomized clinical trial comparing the effects of short-term adaptation to a well-formulated KD and MD on markers of bone health and muscle function in older adults. The investigators will supply fresh prepared meals to achieve high adherence to the dietary interventions and adequate contrast in metabolic state between treatment groups.
Potential participants will complete a screening process so the investigators can determine whether potential participants are eligible to enroll in the study. At the first screening visit, the study team will measure blood pressure, height, and weight. Individuals will complete questionnaires that collect information about their health history, dietary intake, and physical activity habits. No more than 50 mL of blood will be collected from potential participants to run routine clinical lab tests to evaluate health status.
If an individual remains eligible after the first screening visit, they will be invited to complete a 24-hour urine collection (at home) and to schedule a second screening visit. At the second screening visit, a physician will conduct a physical exam and assess their body composition with an x-ray technology called dual-energy x-ray absorptiometry (DEXA or DXA).
If an individual remains eligible after the second screening visit, they will be invited to enroll in the dietary intervention study. Once enrolled, the participant will be assigned to either a very low carbohydrate ketogenic dietary pattern or a Mediterranean dietary pattern. The investigators will provide most of the food the participant will need each day in the form of a nutrition shake (breakfast) and two prepared meals (lunch and dinner). A study dietitian will be available to provide continuous support through a secure messaging app.
While in the dietary intervention phase of the study, participants will come to the UF Clinical and Translational Science Building once a week for 6 weeks. The study team will measure participant blood pressure and weight at each visit. At the first, middle, and final visits, the study team will collect a blood sample and urine sample from participants for lab testing, and participants will complete a short series of tests that measure physical performance.
Our ultimate research goal is to determine the effects of KD on body composition and clinically relevant measures of bone health and muscle function, as those data are needed to (1) inform the benefit-risk assessment for an older patient who is considering longer term adherence to KD therapy and (2) optimize the effectiveness of KD for age-related conditions.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Very low carbohydrate ketogenic diet provided for six weeks
Mediterranean diet provided for six weeks
Time frame: Monthly. Up to 24 months.
Number of participants enrolled in dietary intervention phase per month
Time frame: Monthly. Up to 24 months.
Number of participants deemed ineligible / number of participants screened * 100
Time frame: Either after the endline visit or when participant is withdrawn or withdraws from study
Percentage of participants enrolled in dietary intervention phase who complete at least 6 intervention study visits including baseline, middle, and final visit.
Time frame: Either after the endline visit or when participant is withdrawn or withdraws from study
Treatment-specific adherence rates to protocol as evidenced by (1) dietary intake (2) blood ketone concentrations
Time frame: Pre-intervention; during the intervention (at 3 and 6 weeks into the intervention)
Serum CTX, urine NTX, serum TRACP-5b, serum P1NP, serum BSAP, serum osteocalcin
Time frame: Pre-intervention; during the intervention (at 6 weeks into the intervention)
Body Fat Percentage measured by dual-energy x-ray absorptiometry
Time frame: Pre-intervention; during the intervention (at 6 weeks into the intervention)
Fat Mass Index measured by dual-energy x-ray absorptiometry
Time frame: Pre-intervention; during the intervention (at 6 weeks into the intervention)
Visceral Adipose Tissue (VAT) measured by dual-energy x-ray absorptiometry
Time frame: Pre-intervention; during the intervention (at 6 weeks into the intervention)
Fat Free Mass Index measured by dual-energy x-ray absorptiometry
Time frame: Pre-intervention; during the intervention (at 6 weeks into the intervention)
Skeletal Muscle Mass measured by dual-energy x-ray absorptiometry
Time frame: Pre-intervention; during the intervention (at 6 weeks into the intervention)
Appendicular Lean Mass to Height Ratio measured by dual-energy x-ray absorptiometry
Time frame: Pre-intervention; during the intervention (at 6 weeks into the intervention)
Resting Metabolic Rate estimated from dual-energy x-ray absorptiometry data
Time frame: Pre-intervention; during the intervention (at 3 and 6 weeks into the intervention)
A standardized report from 24-hour urine studies
Time frame: Pre-intervention; during the intervention (at 3 and 6 weeks into the intervention)
Handgrip strength measured by dynamometer
Time frame: Pre-intervention; during the intervention (at 3 and 6 weeks into the intervention)
Results of balance tests performed as part of the short physical performance battery
Time frame: Pre-intervention; during the intervention (at 3 and 6 weeks into the intervention)
Results of gait speed tests performed as part of the short physical performance battery
Time frame: Pre-intervention; during the intervention (at 3 and 6 weeks into the intervention)
Results of chair stand tests performed as part of the short physical performance battery
Time frame: Pre-intervention; during the intervention (at 6 weeks into the intervention)
Relative expression of circadian genes in whole blood collected in PAXgene blood RNA tubes
Time frame: Pre-intervention; during the intervention (at 3 and 6 weeks into the intervention)
Circulating concentrations of vitamin D metabolites
Time frame: Pre-intervention; during the intervention (at 3 and 6 weeks into the intervention)
Circulating concentration of parathyroid hormone
Time frame: Pre-intervention; during the intervention (at 3 and 6 weeks into the intervention)
Anion gap from comprehensive metabolic panel
Time frame: Pre-intervention; during the intervention (at 3 and 6 weeks into the intervention)
Circulating insulin concentration
Time frame: Pre-intervention; during the intervention (at 3 and 6 weeks into the intervention)
Circulating glucagon concentration
Time frame: Pre-intervention; during the intervention (at 3 and 6 weeks into the intervention)
Circulating IGF-1 concentration
Time frame: Pre-intervention; during the intervention (at 3 and 6 weeks into the intervention)
Circulating beta-hydroxybutyrate concentration
Time frame: Pre-intervention; during the intervention (at 3 and 6 weeks into the intervention)
Total Cholesterol, Triglycerides, HDL Cholesterol, LDL-Cholesterol, Non-HDL Cholesterol
Time frame: Pre-intervention; during the intervention (at 3 and 6 weeks into the intervention)
Serum cystatin C
University of Florida
Other
Effects of a Very Low Carbohydrate Ketogenic Diet Versus Mediterranean Diet on Markers of Bone Health and Muscle Function in Older Adults: A Pilot Study
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04862481
Aging, Atrophy
Slagelse, Region Sjælland, Denmark
View Trial DetailsNCT07563777
Activities of Daily Living, Aging
Boulder, Colorado, United States
View Trial DetailsNCT05266976
Aging, Bone Diseases
Aurora, Colorado, United States
View Trial DetailsNCT06068803
Acid-Base Imbalance, Acidosis
Bath, Somerset, United Kingdom
View Trial Details